According to El Faro de Vigo, the research group of the University of Santiago de Compostela (USC), BioFarma, has just joined a project that explores the role of new inhibitors aimed at epigenetic targets against cancer, led by the company Oryzon Genomics, with which he has already collaborated since 2008 in other projects. "We intend to act on certain proteins that modulate the expression of certain genes related to cancer without modifying the information contained in the DNA", explains Mabel Loza, coordinator of the BioFarma group, applied to the discovery of drugs, regarding this study.